Elicio Therapeutics (ELTX) Amortization of Deferred Charges (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Amortization of Deferred Charges data on file, last reported at $243000.0 in Q1 2026.

• Quarterly Amortization of Deferred Charges rose 8.0% year-over-year to $243000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $942000.0 (up 7.78% YoY) and the FY2025 annual result came in at $924000.0, up 7.82% from the prior year.
• Amortization of Deferred Charges grew to $243000.0 in Q1 2026, from $237000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $397000.0 in Q2 2023 to a low of $87000.0 in Q2 2022.
• A 5-year average of $217437.5 and a median of $214500.0 in 2024 frame the typical range for Amortization of Deferred Charges.
• Annual changes were most pronounced in 2022 — Amortization of Deferred Charges sank 87.76% — and 2023, when it jumped 356.32%.
• Tracing ELTX's Amortization of Deferred Charges over 5 years: stood at $194000.0 in 2022, then gained by 6.19% to $206000.0 in 2023, then grew by 6.8% to $220000.0 in 2024, then increased by 7.73% to $237000.0 in 2025, then gained by 2.53% to $243000.0 in 2026.
• The last three Amortization of Deferred Charges figures came in at $243000.0 (Q1 2026), $237000.0 (Q4 2025), and $234000.0 (Q3 2025), per Business Quant data.